Phase III REACH2 Study Demonstrates Significant Improvements from Ruxolitinib Therapy
Data from the phase III REACH2 study indicated that ruxolitinib therapy led to significant improvements in efficacy outcomes in patients with steroid-refractory acute graft-versus-host disease.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
More News: Cancer & Oncology | Study